CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

Dow Jones

Mar 29

By Kelly Cloonan

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.

The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months.

The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines.

BioNTech first filed a lawsuit regarding the patent in 2023.

After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1.

"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology," said CureVac Chief Executive Dr. Alexander Zehnder.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 28, 2025 12:45 ET (16:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523688154"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523688154\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2523688154?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-29 00:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523688154","market":"hk","top_or_hot":-1,"title":"CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. \n</p>\n<p>\n  The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines. \n</p>\n<p>\n  BioNTech first filed a lawsuit regarding the patent in 2023. \n</p>\n<p>\n  After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1. \n</p>\n<p>\n  \"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology,\" said CureVac Chief Executive Dr. Alexander Zehnder. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 28, 2025 12:45 ET (16:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-29 00:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. \n</p>\n<p>\n  The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines. \n</p>\n<p>\n  BioNTech first filed a lawsuit regarding the patent in 2023. \n</p>\n<p>\n  After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1. \n</p>\n<p>\n  \"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology,\" said CureVac Chief Executive Dr. Alexander Zehnder. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 28, 2025 12:45 ET (16:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVAC","symbol_name":"CureVac B.V.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2523688154","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523688154","pubTimestamp":1743180300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months.The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines.BioNTech first filed a lawsuit regarding the patent in 2023.After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1.\"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology,\" said CureVac Chief Executive Dr. Alexander Zehnder.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVAC":"CureVac B.V.","BK4139":"生物科技","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"translate_title":"BioNTech诉讼中专利确认，CureVac股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVAC":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. \n\n\n  The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months. \n\n\n  The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines. \n\n\n  BioNTech first filed a lawsuit regarding the patent in 2023. \n\n\n  After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1. \n\n\n  \"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology,\" said CureVac Chief Executive Dr. Alexander Zehnder. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 12:45 ET (16:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}